Oligonucleotide Therapeutics Market to Reach $17.7B

- ASO therapies are single-stranded DNA or RNA molecules that bind to target mRNA to prevent protein translation, while siRNAs are double-stranded RNA that leverage the RNA interference (RNAi) pathway to cleave target mRNA. Notable FDA-approved ASOs include Nusinersen for spinal muscular atrophy, while Patisiran, an siRNA therapeutic, treats hereditary transthyretin-mediated amyloidosis. ASOs can be delivered "naked" due to chemical modifications ensuring stability, whereas siRNAs often require nanoparticle or lipid-based carriers for effective delivery. - A primary manufacturing challenge is the scalability of solid-phase synthesis, the standard method, which has limitations in batch size and generates significant organic and aqueous waste. The process requires high-purity, expensive raw materials, and the cumulative yield decreases with each nucleotide addition, increasing costs and waste, especially for longer, more complex sequences. These factors contribute to a high process mass intensity (PMI), a measure of the environmental impact of the synthesis. - To overcome the limitations of solid-phase synthesis, companies are exploring alternative manufacturing methods such as solution-phase synthesis, fragment assembly, and enzymatic synthesis to achieve higher yields and improve sustainability. There is also a focus on developing automated, integrated platforms that combine chemistry, discovery, delivery, and manufacturing to accelerate timelines from the lab to the clinic. AI and machine learning are being implemented to optimize process parameters, improve impurity analysis, and reduce the number of experiments needed, thus lowering costs and development time. - Efficient in-vivo delivery, particularly to tissues outside the liver, remains a major hurdle for many oligonucleotide candidates. Current successful delivery systems primarily include lipid nanoparticles (LNPs) and GalNAc conjugation for liver-targeted delivery. Innovations to overcome this include the development of antibody-oligonucleotide conjugates (AOCs), peptide conjugates, and various nanocarriers like nanospheres and DNA nanostructures to improve tissue specificity and cellular uptake. - Major players in the therapeutic space include Ionis Pharmaceuticals, a pioneer with the first approved ASO drug, Alnylam Pharmaceuticals, Biogen, and Sarepta Therapeutics. The manufacturing and services sector includes companies like Danaher (through its subsidiaries IDT and Cytiva), Thermo Fisher Scientific, and Merck KGaA, which provide synthesis equipment, reagents, and custom synthesis services. Strategic partnerships are common, such as Ionis's collaborations with AstraZeneca and Biogen, and Wave Life Sciences' partnerships with GSK and Takeda. - While biotech funding saw a correction in 2022-2023 after a peak in 2021, significant capital remains available for programs with strong science and clear regulatory paths. However, the cell and gene therapy sector, including oligonucleotides, has faced heightened investor caution due to high manufacturing costs and long development timelines, leading to a drop in venture funding from its 2021 high. Despite this, investment continues to flow into companies with novel technologies, particularly those addressing manufacturing and delivery bottlenecks.